Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients

Basit Öğe Kaydı
dc.contributor.authorÇakırca, Mustafa
dc.contributor.authorKaratoprak, Cumali
dc.contributor.authorZorlu, Mehmet
dc.contributor.authorKıskaç, Muharrem
dc.contributor.authorKanat, Mustafa
dc.contributor.authorÇıkrıkçıoğlu, Mehmet Ali
dc.contributor.authorSoysal, Pınar
dc.contributor.authorHurşitoğlu, Mehmet
dc.contributor.authorÇamlı, Ahmet Adil
dc.contributor.authorErkoç, Reha
dc.contributor.authorAbdul-Ghani, Muhammad
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:51:52Z
dc.date.available10.07.201910:49:13
dc.date.available2019-07-10T19:51:52Z
dc.date.issued2014
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.descriptionWOS: 000331555100001
dc.descriptionPubMed ID: 24627624
dc.description.abstractAims: A close association has been demonstrated between increased cardiovascular risk and high asymmetric dimethylarginine (ADMA) levels in type 2 diabetes mellitus (DM) patients. We planned to measure serum ADMA levels in type 2 DM patients using vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. Materials and methods: A total of 68 type 2 DM patients who were on metformin were enrolled in the study. Based on the glycemic levels of patients, vildagliptin was added on to treatment in 33 patients. Patients were followed for 6 months. Serum ADMA, C-reactive protein, and fibrinogen levels were compared in groups of patients using metformin or metformin + vildagliptin, after 6 months. Results: Serum ADMA levels were found to be significantly lower in the group using vildagliptin compared to the group using metformin + vildagliptin (P<0.001). However, serum C-reactive protein and fibrinogen levels were statistically similar in the two study groups (P=0.34 and P=0.23, respectively). Conclusion: Metformin + vildagliptin treatment was observed to lower serum ADMA levels in type 2 DM patients. Our findings notwithstanding, large-scale prospective randomized controlled studies are warranted to conclude that vildagliptin provides cardiovascular protection along with diabetes regulation.
dc.identifier.citationÇakırca, M., Karatoprak, C., Zorlu, M., Kıskaç, M., Kanat, M., Çıkrıkçıoğlu, M.A. ... Abdul-Ghani, M. (2014). Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients. Drug Design, Development and Therapy, 8, 239-243. https://dx.doi.org/10.2147/DDDT.S52545
dc.identifier.doi10.2147/DDDT.S52545
dc.identifier.endpage243
dc.identifier.issn1177-8881
dc.identifier.scopusqualityQ1
dc.identifier.startpage239
dc.identifier.urihttps://dx.doi.org/10.2147/DDDT.S52545
dc.identifier.urihttps://hdl.handle.net/20.500.12511/2299
dc.identifier.volume8
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherDove Medical Press
dc.relation.ispartofDrug Design, Development and Therapyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsAttribution-NonCommercial 3.0 Unported*
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by-nc/3.0/*
dc.subjectAsymmetric Dimethylarginine (ADMA)
dc.subjectDipeptidyl Peptidase-4 (DPP-4) Inhibitor
dc.subjectVildagliptin
dc.subjectType 2 Diabetes Mellitus
dc.titleEffect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Kanat, Mustafa--2014.pdf
Boyut:
261.97 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu